

IFW



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this **INFORMATION DISCLOSURE STATEMENT** and documents submitted therewith are being deposited with the United States Postal Service as first class mail, postage prepaid thereon, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

Ariel Fletcher
Ariel Fletcher

11/16/2004
Date

Applicant: Webb, et al.)
) Group: 1644
Serial No.: 10/822,173)
) Confirmation No.: 3667
Filed: April 8, 2004)
) Examiner: Unassigned
For: MHC CLASS II ANTIGEN- PRESENTING SYSTEMS AND METHODS FOR ACTIVATING CD4 ⁺ T CELLS)
) Our Ref.: TSRI 536.1 Con 1
)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In recognition of its continuing duty to disclose pursuant to 37 CFR §1.56, Applicant hereby submits the present Information Disclosure Statement in compliance therewith.

Pursuant to 37 CFR §1.98(d), enclosed herewith is a copy of 1) the Information Disclosure Statement and 2) the accompanying PTO Form 1449 filed in application 09/715,891 which refers to and also includes Information Disclosure Statements filed in other related applications. Application 09/715,891 was filed on November 17, 2000, now pending, to which the present application is related by continuation. Also, pursuant to 37 CFR §1.98(d),

copies of the above references are not submitted herewith, as they are available in the related patent application 09/715,891 and other related applications.

Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Information Disclosure Statement may be material pursuant to 37 CFR §1.56, it shall not be construed to be an admission that the cited information is, or is considered to be, material to patentability unless specifically designated as such.

Applicants are filing the present statement pursuant to 37 CFR §1.97(b) insofar as this statement is being filed within three months of the filing of the application and/or before the mailing date of a first Office Action.

Also, in accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR §1.56 exists.


Respectfully submitted,

Nov. 16, 2004
Date

Michael J. McCarthy
Michael J. McCarthy, Reg. No. 46,910

THE SCRIPPS RESEARCH INSTITUTE
Office of Patent Counsel
10550 North Torrey Pines Road
Mail Drop TPC-8
La Jolla, CA 92037
(858) 784-2937

P:\NancyB\WP\2004\IDS\SCR2372P



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT and documents submitted therewith are being deposited with the United States Postal Service as first class mail, postage prepaid thereon, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Ariel Fletcher

Ariel Fletcher

1/15/2003

Date of Deposit

Applicant: Webb, et al.

Serial No.: 09/715,891

Filed: November 17, 2000

For: MHC CLASS II ANTIGEN PRESENTING
SYSTEMS AND METHODS FOR
ACTIVATING CD4⁺ T CELLS

Group Art Unit: 1644

Examiner: A. M. DeCloux

Our Ref.: TSRI 536.1 Div 2

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In recognition of their continuing duty to disclose pursuant to 37 CFR 1.56, Applicants hereby submit the present Information Disclosure Statement and accompanying PTO Form 1449 in compliance therewith.

Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Information Disclosure Statement may be material pursuant to 37 CFR 1.56, it shall not be construed to be an admission that the cited

information is, or is considered to be, material to patentability unless specifically designated as such.

Applicants are filing the present statement pursuant to 37 CFR 1.97 (c). The statement is accompanied by a check in the amount of \$180.00 as payment of the fee set forth in 37 CFR §1.17 (p) in accordance with 37 CFR 1.97(c)(2).

Also, in accordance with 37 CFR 1.97 (g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR 1.56 exists.

Respectfully submitted,

1/15/03
Date

Emily Holmes
Emily Holmes, Reg. No. 40,652

THE SCRIPPS RESEARCH INSTITUTE
Office of Patent Counsel
10550 North Torrey Pines Road
Mail Drop TPC-8
La Jolla, CA 92037
(858) 784-2937

[illegible][illegible]

	2	Galvin, et al., "Murine B7 Antigen Provides a Sufficient Costimulatory Signal for Antigen-Specific and MHC-Restricted T Cell Activation", <u>The Journal of Immunology</u> 149: 3802-3808 (1992)
	3	Baskar, et al, "Tumor Cells Expressing Major Histocompatibility Complex Class II and B7 Activation Molecules Stimulate Potent Tumor-Specific Immunity", <u>Journal of Immunotherapy</u> 14: 209-215 (1993)

EXAMINER	DATE CONSIDERED
----------	-----------------

P:\NancyB\WP\2003\IDS\SCR2289P.FORM1449




PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT and documents submitted therewith are being deposited with the United States Postal Service as first class mail, postage prepaid thereon, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.



Tami Barnas



Date

Applicant:	Webb, et al.)	
)	Group: 1644
Serial No.:	09/715,891)	
)	
Filed:	November 17, 2000)	Examiner: Unassigned
)	
For:	MHC CLASS II ANTIGEN-PRESENTING)	
	SYSTEMS AND METHODS FOR)	Our Ref.: TSRI 536.1 Div 2
	ACTIVATING CD4 ⁺ T CELLS)	
)	
)	

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In recognition of its continuing duty to disclose pursuant to 37 CFR §1.56, Applicant hereby submits the present Information Disclosure Statement in compliance therewith.

Pursuant to 37 CFR §1.98(d), enclosed herewith is a copy of 1) the Information Disclosure Statement and 2) the accompanying PTO Form 1449 filed in the application 09/194,285, to which the present application is related by division, filed on April 12, 1999, now pending. Also, pursuant to 37 CFR §1.98(d), copies of the above references are not submitted herewith, as they are available in the related patent application 09/194,285.

Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Information Disclosure Statement may be material pursuant to 37 CFR §1.56, it shall not be construed to be an admission that the cited information is, or is considered to be, material to patentability unless specifically designated as such.

Applicants are filing the present statement pursuant to 37 CFR §1.97(b) insofar as this statement is being filed within three months of the filing of the application/before the mailing date of a first Office Action.

Also, in accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR §1.56 exists.

Respectfully submitted,

3/29/01
Date

Emily Holmes
Emily Holmes, Reg. No. 40,652

THE SCRIPPS RESEARCH INSTITUTE
Office of Patent Counsel
10550 North Torrey Pines Road
Mail Drop TPC-8
La Jolla, CA 92037
(858) 784-2937

P:\TAMI\2001\EH\IDS\SCR2289P.IDS.FORM.REF.PREV.NO.FEE



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT and documents submitted therewith are being deposited with the United States Postal Service as first class mail, postage prepaid thereon, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Tami Barnas

Tami Barnas

3/14/01

Date of Deposit

Applicant:	Webb, et al.)	
)	
Serial No.:	09/194,285)	Group Art Unit: 1644
)	
Filed:	April 12, 1999)	Examiner: F.P. VanderVegt
)	
For:	MHC CLASS II ANTIGEN)	
	PRESENTING SYSTEMS AND)	Our Ref.: TSRI 536.1
	METHODS FOR ACTIVATING)	
	CD4 ⁺ T CELLS)	
)	

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In recognition of their continuing duty to disclose pursuant to 37 CFR 1.56, Applicants hereby submit the present Information Disclosure Statement and accompanying PTO Form 1449 in compliance therewith.

Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Information Disclosure Statement may be material pursuant to 37 CFR 1.56, it shall not be construed to be an admission that the cited

information is, or is considered to be, material to patentability unless specifically designated as such.

Applicants are filing the present statement pursuant to 37 CFR 1.97 (c). The statement is accompanied by a check in the amount of \$180.00 as payment of the fee set forth in 37 CFR §1.17 (p) in accordance with 37 CFR 1.97(c)(2).

Also, in accordance with 37 CFR 1.97 (g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR 1.56 exists.


Respectfully submitted,

3/14/01
Date

Emily Holmes
Emily Holmes, Reg. No. 40,652

THE SCRIPPS RESEARCH INSTITUTE
Office of Patent Counsel
10550 North Torrey Pines Road
Mail Drop TPC-8
La Jolla, CA 92037
(858) 784-2937

FORM PTO-1449. U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY DOCKET NO. TSRI 536.1		SERIAL NO. 09/194,285
	APPLICANT Webb, et al.		
	FILING DATE April 12, 1999	GROUP 1644	



U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
		5,242,687	9/7/93	Tykocinski, et al.			
		5,583,031	12/10/96	Stern			
		5,529,921	6/25/96	Peterson, et al.			
		5,314,813	5/24/94	Peterson, et al.			
		5,395,760	3/7/95	Smith, et al.			

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	1	Hemler, et al., Adhesive protein receptors on hematopoietic cells, 1998, <i>Immunology Today</i> , 9(4):109-114.
	2	Ratnofsky, et al., Expression and function of CD8 in a murine T cell hybridoma, 1987, <i>J. Exp. Med.</i> , 166:1747-1757
	3	Sette, et al., Antigen analogs/MHC complexes as specific T cell receptor antagonists, 1994, <i>Annu. Rev. Immunol.</i> , 12:413-431.
	4	Tan, et al., Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1, 1993, <i>J. Exp. Med.</i> , 177:165-173.
	5	Brown, et al., CD27-CD27 ligand/CD70 interactions enhance alloantigen-induced proliferation and cytolytic activity in CD8+ T lymphocytes, 1995, <i>J. Immunol.</i> , 154:3686-3695.
	6	Morris, et al., An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules, 1994, <i>Nature</i> , 368:551-554.
	7	
	8	
	9	
	10	
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.